Gold Star Distribution recalled various feminine hygiene products on December 26, 2025. The recall affects brands including KOTEX and ALWAYS due to potential rodent contamination in their distribution center. Consumers should stop using these products immediately and follow manufacturer instructions for return.
Potential exposure of rodents and rodent activity in the distribution center.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact GOLD STAR DISTRIBUTION INC or your healthcare provider for instructions. Notification method: Press Release
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled products include KOTEX FREEDOM MAXI NO WINGS (48 ct), ALWAYS THIN LINERS UNSCENTED (12 ct), ALWAYS THIN LINERS SCENTED (12 ct), and others. The specific UPC codes for these products are provided in the recall notice. These items were distributed nationwide in the United States, particularly in Minnesota.
The recall stems from potential exposure to rodents and rodent activity at the distribution center. This situation poses a health risk to consumers, especially considering the nature of these products.
No specific incidents of illness or injury have been reported as of the recall date. The recall was classified as Class II, indicating a moderate health risk.
Consumers should stop using the affected products immediately. Contact Gold Star Distribution Inc. or your healthcare provider for further instructions on returning the products.
For more information, consumers can visit the FDA recall page at https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=Z-1182-2026.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.